
BiotechTV - News
Raymond James Biotech Innovation Symposium: Septerna is developing oral small molecules that target GPCRs, it now has two programs in the clinic
7 min•14 april 2026
Om avsnittet
Co-Founder and CEO Jeffrey Finer describes how Septerna is able to screen for GPCR targets in ways that have not previously been possible. Plus, an overview of programs targeting MRGPRX2, PTH1R, and a collaboration with Novo on obesity.
Fler avsnitt
Visa alla avsnitt av BiotechTV - NewsBiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.